单克隆抗体
医学
药品
抗体-药物偶联物
乳腺癌
结合
抗体
癌症
癌症研究
免疫学
药理学
内科学
数学分析
数学
作者
Swati Saini,Nisha Gulati,Rajendra Awasthi,Vimal Arora,Sachin Kumar Singh,Shobhit Kumar,Gaurav Gupta,Kamal Dua,Rakesh Pahwa,Harish Dureja
出处
期刊:Current Drug Delivery
[Bentham Science]
日期:2023-07-31
卷期号:21 (7): 993-1009
被引量:11
标识
DOI:10.2174/1567201820666230731094258
摘要
When breast cells divide and multiply out of control, it is called breast cancer. Symptoms include lump formation in the breast, a change in the texture or color of the breast, or a discharge from the nipple. Local or systemic therapy is frequently used to treat breast cancer. Surgical and radiation procedures limited to the affected area are examples of local management. There has been significant worldwide progress in the development of monoclonal antibodies (mAbs) since 1986, when the first therapeutic mAb, Orthoclone OKT3, became commercially available. mAbs can resist the expansion of cancer cells by inducing the destruction of cellular membranes, blocking immune system inhibitors, and preventing the formation of new blood vessels. mAbs can also target growth factor receptors. Understanding the molecular pathways involved in tumor growth and its microenvironment is crucial for developing effective targeted cancer therapeutics. Due to their unique properties, mAbs have a wide range of clinical applications. Antibody-drug conjugates (ADCs) are drugs that improve the therapeutic index by combining an antigen-specific antibody with a payload. This review focuses on the therapeutic applications, mechanistic insights, characteristics, safety aspects, and adverse events of mAbs like trastuzumab, bevacizumab, pertuzumab, ertumaxomab, and atezolizumab in breast cancer treatment. The creation of novel technologies utilizing modified antibodies, such as fragments, conjugates, and multi-specific antibodies, must be a central focus of future studies. This review will help scientists working on developing mAbs to treat cancers more effectively.
科研通智能强力驱动
Strongly Powered by AbleSci AI